Canada: Recall, Report, Relabel: Bill C-17 Increases Oversight Of Drugs And Medical Devices

Bill C-17, An Act to Amend the Food and Drugs Act (Bill), received royal assent on November 6, 2014. The Bill applies to medical devices and prescription and over-the-counter drugs (collectively, therapeutic products), but does not apply to natural health products.

The Bill grants the Minister of Health (Minister) substantial new powers, including the power to order recalls, collect post-market safety information, and implement label changes. The Bill also imposes increased penalties for noncompliance and, perhaps most controversially, permits the disclosure of confidential business information relating to therapeutic products without consent or notice under certain circumstances. The Bill is in line with Health Canada's general trend over the last few years towards increased safety regulations, including the Canada Consumer Product Safety Act, which came into force in 2011 and the Safe Food for Canadians Act, which was passed in 2012 but is not yet in force.

The salient features of the Bill are set out below.

NEW OBLIGATIONS FOR MANUFACTURERS/SELLERS

Bill C-17 contains numerous provisions that impose additional post-market obligations on manufacturers and/or sellers of therapeutic products. For instance, the Bill allows the Minister to:

  • Order the seller of a therapeutic product to recall the product if the Minister believes the product presents a serious or imminent risk of injury to health
  • Order a manufacturer to modify a therapeutic product's label or to modify or replace its packaging if the Minister believes that doing so is necessary to prevent injury to health
  • Order a manufacturer to conduct certain assessments, tests, or studies in respect of a therapeutic product, and to provide the results to the Minister.

Many Canadians were unaware that prior to this Bill, the Minister did not have the power to recall a therapeutic product although the Minister had the ability to issue unilateral communications regarding the safety of a therapeutic product, suspend a company's product approval and/or issue other orders regarding the sale of an impugned product.

The Bill also enables the Governor in Council to make regulations that would trigger additional obligations, such as regulations requiring manufacturers to disclose clinical trial data to the public in a prescribed time and manner, and to provide safety-related information (e.g. regarding labelling changes that have taken place outside Canada) to the Minister.

CONCERNS REGARDING CONFIDENTIAL BUSINESS INFORMATION

The Bill sets out several circumstances under which the Minister may disclose confidential business information (CBI), which may include trade secrets. Specifically, the Bill allows the Minister to disclose or release CBI without notice or consent:

  • To anyone, including the public, if the Minister believes the product may present a serious risk of injury to human health
  • To a government (including foreign government), a government adviser, or a person who carries out functions relating to the protection or promotion of human health or safety of the public, if the purpose of the disclosure is related to the protection or promotion of human health or the safety of the public.

Further, the Bill permits the Governor in Council to make regulations designating certain business information as non-confidential (or specifying circumstances in which CBI ceases to be confidential) and allowing such information to be disclosed without notice or consent.

This new disclosure regime, which is more permissive than regimes in the United States and the European Union, has raised concerns about Canada's compliance with international trade obligations relating to the protection of trade secrets and other confidential data. In response, Minister Rona Ambrose has publicly confirmed her commitment that any disclosure of CBI will only occur in a manner that is consistent with Canada's treaty obligations.

NEW OBLIGATIONS FOR HEALTH-CARE INSTITUTIONS

In addition, the Bill allows the Minister to make regulations requiring health-care institutions to report adverse drug reactions or medical device incidents. The switch from voluntary to mandatory reporting would require significant new compliance measures by affected institutions.

TOUGHER PENALTIES

Increased penalties for contravention accompany the new obligations under the Bill. For instance, a person who contravenes a provision of the Food and Drugs Act or its regulations relating to a therapeutic product is now liable for a monetary penalty of up to C$5 million per day and/or imprisonment for up to two years. The Bill also sets out additional officer, director and agent liability where such individuals direct, authorize, assent to, acquiesce or participate in an offence committed by a corporation, and such individuals are liable to the same strict penalties set out above.

These tougher penalty provisions are counterbalanced by a new due diligence defence to prosecutions for offences under the legislation. Note, however, that the due diligence defence cannot be evoked where a person has knowingly made false or misleading statements to Health Canada or has knowingly or recklessly caused a serious risk of injury to human health in contravening a provision relating to a therapeutic product. In such cases, the maximum penalties set out above do not apply and harsher punishments may be imposed on a discretionary basis by the court.

MOVING FORWARD

Most of the Bill came into force upon royal assent, including the tougher penalties and the Minister's new powers to order recalls, require labelling changes and disclose CBI and new information about a product. However, there are a few provisions that will come into force at a later date and after relevant regulations have been developed, including the power to publicly disclose negative regulatory decisions. Companies should monitor the regulatory landscape closely, as portions of the Bill will be further defined through regulation in the coming months and years.

Given the new obligations imposed under the Bill and the significant consequences of a violation, pharmaceutical and medical devices companies should review their compliance programs carefully to ensure that any applicable post-market requirements can be met. A good compliance program both reduces the likelihood of non-compliance with the Bill and may also be used as evidence of due diligence in the event a violation occurs.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
23 Nov 2018, Other, Toronto, Canada

Cybersecurity, including data privacy and security obligations, has become a critical chapter in every company’s risk management playbook.

28 Nov 2018, Speaking Engagement, Toronto, Canada

Arbitration has a number of advantages and some disadvantages for the resolution of domestic and international commercial disputes.

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions